Alfasigma Spa has signed an agreement to acquire the entire share capital of Sofar SpA, an Italian pharmaceutical company with over half a century of history, operating in the research, production and marketing of drugs, medical devices and food supplements. Alfasigma with this acquisition adds to its portfolio the products of Sofar, known in particular for Pentacol *, Enterolactis *, Gerdoff *, Cistiflux * and Siler *.
Sofar closed 2021 with a turnover of over 113 million euros, double-digit growth compared to the previous year. The company, with over 54 years of history, 150 references marketed in more than 10 therapeutic areas and over 300 employees, owns an advanced research laboratory located in Bergamo and a manufacturing plant in Trezzano Rosa (Milan). Alfasigma is one of the leading pharmaceutical companies with Italian capital, with a consolidated turnover of over one billion euros in 2021, research centers in Bologna and Pomezia, three production plants in Italy and two abroad, and about 3 thousand employees.
Both companies are focused on the gastrointestinal area. Sofar develops about 80% of its activity in this therapeutic area and has concentrated research on the microbiota within the Kilometro Rosso Science and Technology Park in Bergamo. Alfasigma is developing a product pipeline focused on the gastrointestinal area, in which it can make the most of its important scientific know-how. The integration of the two companies will lead to the expansion of Alfasigma’s product range in Italy and on foreign markets.
“This acquisition – declares Stefano Golinelli, president of Alfasigma – allows our company a decisive consolidation on the Italian market and a further focus on the gastroenterological area. This acquisition will contribute to the ambitious growth strategy designed for our company”.
“Our tradition of innovation and the company’s success today come to fruition by joining an already established group such as Alfasigma – says Andrea Biffi, CEO of Sofar – This operation once again consolidates the value of made in Italy in the field pharmaceutical and, at the same time, creates an important opportunity for growth and internationalization, confirming the work done by our company in over half a century of history “.
For the CEO of Alfasigma, Francesco Balestrieri, “the acquisition of Sofar marks a first important milestone in the growth path that the board has defined for Alfasigma. Sofar’s portfolio not only offers complementarity from a therapeutic area point of view in Italy , but also an important international growth platform. We expect the acquisition to be completed in October and the integration operations to commence in the final quarter of 2022. ”